Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Clinical trial NCT03736837 · COMPLETED
Trial details
- NCT number
- NCT03736837
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-01
- Primary completion
- 2021-01-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.